308 related articles for article (PubMed ID: 22149368)
21. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
22. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
23. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
24. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
[TBL] [Abstract][Full Text] [Related]
25. HIV nucleoside reverse transcriptase inhibitors.
Amblard F; Patel D; Michailidis E; Coats SJ; Kasthuri M; Biteau N; Tber Z; Ehteshami M; Schinazi RF
Eur J Med Chem; 2022 Oct; 240():114554. PubMed ID: 35792384
[TBL] [Abstract][Full Text] [Related]
26. Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents.
Neely M; Rutstein R; Del Bianco G; Heresi G; Barton T; Wiznia A; Wiegand R; Wheeling T; Bohannon B; Dominguez K;
Pediatr Infect Dis J; 2013 Sep; 32(9):e370-6. PubMed ID: 24008749
[TBL] [Abstract][Full Text] [Related]
27. Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains.
Yu F; Li W; Wang L; Dai Y; Lu X; Wang Q; Xie L; Jiang S
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004408
[TBL] [Abstract][Full Text] [Related]
28. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
29. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
30. Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis.
Chowers M; Gottesman BS; Leibovici L; Schapiro JM; Paul M
Eur J Clin Microbiol Infect Dis; 2010 Jul; 29(7):779-86. PubMed ID: 20449621
[TBL] [Abstract][Full Text] [Related]
31. Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.
Vela JE; Miller MD; Rhodes GR; Ray AS
Antivir Ther; 2008; 13(6):789-97. PubMed ID: 18839780
[TBL] [Abstract][Full Text] [Related]
32. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB; Stone EA; Piacenti FJ
Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
[TBL] [Abstract][Full Text] [Related]
33. Triple nucleoside reverse transcriptase inhibitor therapy in children.
Handforth J; Sharland M
Paediatr Drugs; 2004; 6(3):147-59. PubMed ID: 15170362
[TBL] [Abstract][Full Text] [Related]
34. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
35. HIV/AIDS management in office practice. Antiretroviral therapy.
Hartman AF
Prim Care; 1997 Sep; 24(3):531-60. PubMed ID: 9271691
[TBL] [Abstract][Full Text] [Related]
36. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
Humphreys EH; Chang LW; Harris J
Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
[TBL] [Abstract][Full Text] [Related]
37. Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections.
Ramesh D; Vijayakumar BG; Kannan T
ChemMedChem; 2021 May; 16(9):1403-1419. PubMed ID: 33427377
[TBL] [Abstract][Full Text] [Related]
38. Resistance against reverse transcriptase inhibitors.
O'Brien WA
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S185-92. PubMed ID: 10860904
[TBL] [Abstract][Full Text] [Related]
39. Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
Molina JM; Ene L; Cahn P; Fätkenheuer G; Van Wijngaerden E; Lombaard J; Zakharova N; Van Eygen V; Vanveggel S; Van Solingen-Ristea R
Antivir Ther; 2021 Nov; 26(6-8):95-105. PubMed ID: 35485339
[TBL] [Abstract][Full Text] [Related]
40. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Aug; (8):CD008651. PubMed ID: 20687097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
